DocWire: African American men less likely to use targeted prostate cancer detection method
Study shows that African American men receive MRI-ultrasound biopsies less than white men
The findings of a new study published in the journal Prostate Cancer show that African American males are less likely to use a more targeted biopsy option for prostate cancer detection.
“Black men have a significantly higher incidence and are up to three times more likely to die of prostate cancer than white men,” says Dr. Abhinav Sidana, director of urologic oncology and assistant professor in the Division of Urology at the UC College of Medicine, a UC Health urologist and corresponding author on this study. “MRI-ultrasound biopsy has emerged as a promising option for the detection of prostate cancer. In this study, we wanted to identify differences in use of MRI-ultrasound biopsy between black and white men with possible prostate cancer.”
Featured photo by Colleen Kelley/UC Creative Services
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.
Combination immunotherapy helps overcome melanoma treatment resistance
November 10, 2025
MSN highlighted research led by the University of Cincinnati Cancer Center's Trisha Wise-Draper showing a combination of immunotherapy medications can activate a robust immune response and help overcome treatment resistance in patients with refractory melanoma.